ActiGraph Releases API Supporting Actigraphy Data Collection
ActiGraph, a leading provider of objective physical activity and sleep/wake monitoring solutions for the global research community, announced today the release of an Application Programming Interface (API) to its popular ActiLife analysis software. The newest addition to ActiGraph’s growing technology suite, the ActiLife API was designed to run within closed systems, ensuring that protocol and regulation compliance requirements are not compromised during data collection.
ActiGraph’s new API allows programmatic control of the ActiLife software over a standard socket, allowing users to develop their own custom applications (Java, C#, C++, etc.) which can automate activity monitor deployments and downloads. An active Internet connection is not required and the ActiLife user interface control can be completely blocked from view, allowing full integration and automation of custom client applications. The ActiLife API currently supports all ActiGraph devices, including the company’s newest wireless wGT3X+ and wActiSleep+ monitors.
“The ActiLife API was primarily developed to support the implementation of ActiGraph’s objective monitoring system within drug trials and clinical research studies,” said Jeremy Wyatt, ActiGraph’s Vice President of Software Engineering. “The tremendous value of objective measures within these markets is finally becoming fully understood, and we are focused on developing tools, like the ActiLife API, that deliver data seamlessly in these complex environments.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
